AidaBREAST designation marks PreludeDx’s second FDA Breakthrough Device, following DCISionRT® LAGUNA HILLS, Calif., April 29, 2026 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
